{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T10:22:50Z","timestamp":1789381370274,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":1071,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:p>The relationship between plasma protease inhibitor (PI) trough concentrations and hyperlipidemic effects were evaluated retrospectively using data from 2 pilot clinical trials of a double\u2010boosted PI regimen (saquinavir\/lopinavir\/ritonavir) in 25 HIV patients. The patients' median age was 39 years (range, 25\u201360). At baseline, PI\u2010naive patients had a median viral load of 53 500 copies\/mL and median CD4 of 296 cells\/mm<jats:sup>3<\/jats:sup>, while PI\u2010experienced patients had 37 750 copies\/mL and 214 cells\/mm<jats:sup>3<\/jats:sup>. Plasma PI trough concentrations of saquinavir, lopinavir, and ritonavir at week 12 were 520, 4482, and 153 ng\/mL, respectively. At week 12, median fasting lipids increased significantly from baseline: total cholesterol increased from 165 to 189 mg\/dL (P = .0005) and the triglyceride increased from 113 to 159 mg\/dL (P = .001). There were no associations between PI trough concentrations at week 12 and the percent total cholesterol change at week 12. No associations were found between PI trough concentrations and lipid changes in HIV patients on a double\u2010boosted PI regimen (saquinavir\/lopinavir\/ritonavir). Factors other than systemic exposure to PIs (such as host or genetic factors) may modulate the hyperlipidemic effect of PIs.<\/jats:p>","DOI":"10.1177\/0091270009339739","type":"journal-article","created":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T01:12:45Z","timestamp":1264381965000},"page":"392-400","source":"Crossref","is-referenced-by-count":7,"title":["Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Double\u2010Boosted Protease Inhibitor Regimen (Saquinavir\/Lopinavir\/Ritonavir)"],"prefix":"10.1002","volume":"50","author":[{"given":"Martin S.","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Hellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Sheble\u2010Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin J.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Greenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl375"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1310\/HAG3-8YA5-UDQC-36NX"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00506.x"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/135965350701200803","article-title":"Predictive factors for response to a boosted dual HIV\u2010protease inhibitor therapy with saquinavir and lopinavir in extensively pre\u2010treated patients","volume":"12","author":"Hentig N","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1310\/YGKE-7K4V-UF5R-4F1G"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn050"},{"key":"e_1_2_5_8_2","unstructured":"HellingerJ MorrisAB PiscitelliS et al.Pilot study of saquinavir\u2010SGC (Fortovase SQV) 1000 mg twice daily and lopinavir\/ritonavir (Kaletra LPV\/r) in protease inhibitor\u2010experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ). Abstract presented at: Ninth Conference on Retroviruses and Opportunistic Infections; February 24\u201328 2002; Seattle WA. Abstract 451\u2010W."},{"key":"e_1_2_5_9_2","unstructured":"SchoutsenD StieltjesH vanSchaickE NauwelaersD NoijT.Simultaneous analysis of all registered anti\u2010HIV drugs in human plasma by high throughput HPLC\u2010MSMS. Abstract presented at: 21st Montreux Symposium on LC\/MS; November 10\u201312 2004; Montreux Switzerland."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2005.00328.x"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001070-00006"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200403050-00008"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200411050-00005"},{"key":"e_1_2_5_14_2","unstructured":"BoffitoM Collot\u2010TeixeiraS DeLorenzoF et al.Plasma exposure of 100mg once and twice daily decreases HDL and CD36 expression but only twice\u2010daily dosing increases triglycerides: potential effect of RTV on cardiovascular disease. Abstract presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3\u20136 2008; Boston MA. Abstract 930."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90225-8"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.74.5.1045"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.22.2978"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/135965350501000608","article-title":"A randomized trial to evaluate lopinavir\/ritonavir versus saquinavir\/ritonavir in HIV\u20101\u2010infected patients: the MaxCmin2 trial","volume":"10","author":"Dragsted UB","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200203080-00006"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305230-00007"},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1097\/00002030-200007070-00005","article-title":"Importance of protease inhibitor plasma levels in HIV\u2010infected patients treated with genotypic\u2010guided therapy: pharmacological data from the Viradapt Study","volume":"14","author":"Durant J","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-12-199606150-00003"},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1128\/AAC.41.11.2433","article-title":"Exposure\u2010response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy","volume":"41","author":"Vanhove GF","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00002030-199903110-00005","article-title":"Urological complaints in relation to indinavir plasma concentrations in HIV\u2010infected patients","volume":"13","author":"Dieleman JP","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001070-00007"},{"key":"e_1_2_5_26_2","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1097\/00002030-199910220-00011","article-title":"The relationship between ritonavir plasma levels and side\u2010effects: implications for therapeutic drug monitoring","volume":"13","author":"Gatti G","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_5_27_2","unstructured":"deRequena Gonzalez D BonoraS CantaF et al.Atazanavir Ctrough is associated with efficacy and safety: definition of therapeutic range. Abstract presented at: 12th Conference on Retrovirus and Opportunistic Infection; February 22\u201325 2005; Boston MA. Abstract 645."},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200308150-00007"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1089\/108729103322395465"},{"key":"e_1_2_5_30_2","unstructured":"LeGuellecC VeillonS ArsacP et al.High lopinavir plasma concentrations are associated with changes in lipid levels at M6 in HIV\u2010infected patients. Abstract presented at: Sixth International Workshop on Clinical Pharmacology of HIV Therapy; April 28\u201330 2005; Quebec Canada. Abstract 44."},{"key":"e_1_2_5_31_2","unstructured":"TsengA LouftyM PhillipsE WalkerS RachilisA WalmsleyS.The relationship between lipid elevations and lopinavir (LPV) concentrations in HIV\u2010infected patients on LPV\/r\u2010containing salvage regimens. Abstract presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27\u201330 2002; San Diego CA. AbstractH\u20101916."},{"key":"e_1_2_5_32_2","doi-asserted-by":"crossref","unstructured":"CalboreanuA DimetJ TreluyerJM et al.Relation between lopinavir plasma blood concentrations and hypertriglyceridemia in naive and protease inhibitors\u2010experienced patients. Abstract presented at: 10th Conference on Retroviruses and Opportunistic Infections; February 10\u201314 2003; Boston MA. Abstract 526.","DOI":"10.2165\/00128413-200313780-00026"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1310\/8TXF-P814-8JPF-7TRY"},{"key":"e_1_2_5_34_2","unstructured":"BoffitoM BonoraS SiniccoA et al.Lopinavir plasma concentrations and lipid elevation patterns in patients on lopinavir\/ritonavir\u2010containing regimens. Abstract presented at: Fourth international Workshop on Clinical Pharmacology of HIV Therapy; March 27\u201329 2003; Cannes France. Abstract 4.4."},{"key":"e_1_2_5_35_2","unstructured":"BestB MayS WittM et al.Relationship between lopinavir concentration and changes in lipid levels at 24 weeks. Abstract presented at: 11th Conference on Retroviruses and Opportunistic Infections; February 8\u201311 2004; San Francisco CA. Abstract 613."},{"key":"e_1_2_5_36_2","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1177\/135965350701200813","article-title":"Relationships between drug exposure, changes in metabolic parameters and body fat in HIV\u2010infected patients switched to a nucleoside sparing regimen","volume":"12","author":"Autar RS","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.11.3734"},{"key":"e_1_2_5_38_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1177\/135965359900400305","article-title":"Lipid evaluation in HIV\u20101\u2010positive patients treated with protease inhibitors","volume":"4","author":"Schmidt HH","year":"1999","journal-title":"Antivir Ther"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)75347-2"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01449-X"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00007"},{"key":"e_1_2_5_42_2","unstructured":"GometzED GrimmD KingM et al.Association of lipid changes in HAART\u2010treated individuals with apolipoprotein genotypes. Abstract presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5\u20138 2006; Denver CO. Abstract 768."},{"key":"e_1_2_5_43_2","unstructured":"CossarizzaA RivaA PomaZanone B et al.FASI\u2010670 and APOC3 polymorphisms as predictors of lipoatrophy in patients receiving ART. Abstract presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5\u20138 2006; Denver CO. Abstract 767."},{"key":"e_1_2_5_44_2","unstructured":"RanadeK ParkerR PloughmanL et al.A single nucleotide polymorphism in the resistin gene is associated with adverse metabolic changes on HAART: an exploratory pharmacogenetic association study of A5005s the metabolic sub\u2010study of ACTG 384. Abstract presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5\u20138 2006; Denver CO. Abstract 763."},{"key":"e_1_2_5_45_2","unstructured":"DeLucaA DiGiambenedettoS SchwarzJ et al.The effect of polymorphism of the MDR\u20101 gene on the long\u2010term risk of lipodystrophy and dyslipidemia in HIV\u2010infected patients starting ART. Abstract presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5\u20138 2006; Denver CO. Abstract 766."},{"key":"e_1_2_5_46_2","unstructured":"ArnedoM TaffeP FurrerH et al.Modeling the influence of polymorphisms of several genes involved in lipid metabolism on the risk of ART\u2010associated dyslipidemia. Abstract presented at: 13th Conference on Retroviruses and Opportunistic Infections; February 5\u20138 2006; Denver CO. Abstract 764."},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1086\/429295"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270009339739","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270009339739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:25:52Z","timestamp":1697502352000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270009339739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1177\/0091270009339739"],"URL":"https:\/\/doi.org\/10.1177\/0091270009339739","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}